Semin Thromb Hemost 2006; 32(3): 231-245
DOI: 10.1055/s-2006-939434
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Analysis of Risk Factors: The Rationale of the Guidelines of the Czech Hematological Society for Diagnosis and Treatment of Chronic Myeloproliferative Disorders with Thrombocythemia

Jiří Schwarz1 , Robert Pytlík2 , Michael Doubek3 , Yvona Brychtová3 , Petr Dulíček4 , Vít Campr1 , 5 , Leoš Křen6 , Miroslav Penka7
  • 1Clinical Section, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
  • 21st Department of Internal Medicine, 1st Medical Faculty, Charles University, Prague, Czech Republic
  • 3Internal Hematooncological Department, Faculty Hospital Brno-Bohunice, Masaryk University, Brno, Czech Republic
  • 41st Department of Internal Medicine, Faculty Hospital Hradec Králové, Charles University, Hradec Králové, Prague, Czech Republic
  • 5Institute of Pathological Anatomy, 2nd Medical Faculty, Charles University, Faculty Hospital Motol, Prague, Czech Republic
  • 6Department of Pathology, Faculty Hospital Brno-Bohunice, Masaryk University, Brno, Czech Republic;
  • 7Department of Clinical Hematology, Faculty Hospital Brno-Bohunice, Masaryk University, Brno, Czech Republic
Further Information

Publication History

Publication Date:
02 May 2006 (online)

ABSTRACT

The rationale of the Czech Hematological Society guidelines for diagnosis and treatment of Philadelphia chromosome-negative myeloproliferative disorders with thrombocythemia (MPD-T) is reviewed. For diagnosis of MPD-T, the classification according to the World Health Organization or to the Rotterdam criteria is preferred because they distinguish true essential thrombocythemia from prefibrotic or early fibrotic idiopathic myelofibrosis and prepolycythemic polycythemia vera. The histopathology-based nosological distinction provided by these classifications yields valuable information on prognosis (including the risks of transition into secondary acute myeloid leukemia and myelofibrosis). Another serious complication in MPD-T is thrombosis (arterial or venous), the main risk factors of which are age, previous thrombosis, platelet counts 350 to 2200 × 109/L (peak at ~900 × 109/L) and the presence of additional thrombophilic risk factors (hereditary thrombophilia, any hypercoagulable state, cardiovascular disease). The hemorrhagic risk starts increasing progressively at platelet counts > 1000 × 109/L. Treatment should be stratified with respect to the thrombotic and hemorrhagic risks. In high-risk patients, thromboreductive therapy is warranted. All of the cytostatic drugs, including hydroxyurea, may be leukemogenic and should be given only to patients > 60 years old, whereas anagrelide or interferon α are preferred in younger individuals. In low-risk patients, antiaggregation therapy is sufficient, unless the platelet count exceeds 1000 × 109/L, which is another indication for thromboreduction. Thrombopheresis is indicated in thrombocythemia > 2000 × 109/L.

REFERENCES

  • 1 Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.  Semin Hematol. 1997;  34 29-39
  • 2 Michiels J J. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia.  Neth J Med. 1997;  51 57-64
  • 3 Michiels J J, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.  Semin Thromb Hemost. 1997;  23 339-347
  • 4 Imbert M, Pierre R, Thiele J, Vardiman J, Brunning R, Flandrin G. Essential thrombocythemia. In: Jaffe E, Harris N, Stein H, Vardiman J WHO Classification of Tumours: Pathology & Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France; IARC Press 2001: 39-41
  • 5 Pierre R, Imbert M, Thiele J, Vardiman J, Brunning R, Flandrin G. Polycythemia vera. In: Jaffe E, Harris N, Stein H, Vardiman J WHO Classification of Tumours: Pathology & Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France; IARC Press 2001: 32-34
  • 6 Thiele J, Pierre R, Imbert M, Vardiman J, Brunning R, Flandrin G. Chronic idiopathic myelofibrosis. In: Jaffe E, Harris N, Stein H, Vardiman J WHO Classification of Tumours: Pathology & Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France; IARC Press 2001: 35-38
  • 7 Michiels J J, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).  Int J Hematol. 2002;  76 133-145
  • 8 Michiels J J. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.  Hematol J. 2004;  5 93-102
  • 9 Michiels J J, Kvasnicka H M, Thiele J. Myeloproliferative disorders. Current Perspectives on Diagnostic Criteria, Histopathology and Treatment in Essential Thrombocythemia, Polycythemia Rubra Vera and Chronic Idiopathic Myelofibrosis. Much Germany; 2005
  • 10 Thiele J, Kvasnicka H M, Werden C, Zankovich R, Diehl V, Fischer R. Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact.  Leuk Lymphoma. 1996;  22 303-317
  • 11 Thiele J, Kvasnicka H M, Diehl V, Fischer R, Michiels J J. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies.  Leuk Lymphoma. 1999;  33 207-218
  • 12 Thiele J, Kvasnicka H M. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.  Ann Hematol. 2003;  82 148-152
  • 13 Schwarz J. Essential thrombocythemia: the experience with anagrelide and its place in the treatment algorithm. [In Czech] (abst). In: XIIIth Czech and Slovak Hematological and Transfusiological Congress. Prague, Czech Republic; 2002: P/154
  • 14 Penka M, Buliková A, Matýšková M, Zavřelová J, Doubek M. Efficacy of anagrelide in the treatment of essential thrombocythemia [In Czech]. (abst). In: XIIIth Czech and Slovak Hematological and Transfusiological Congress. Prague, Czech Republic; 2002: P/155
  • 15 Penka M, Schwarz J, Pytlík R, Doubek M, Brychtová Y, Dulíček P. Practice guidelines for diagnosis and therapy of essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases [In Czech].  Vnitr Lek. 2005;  51 741-751
  • 16 Schwarz J, Penka M. Thrombocytosis and thrombocythemia.  , [In Czech] Vnitr Lek. 2005;  51 861-871
  • 17 Berlin N I. Diagnosis and classification of the polycythemias.  Semin Hematol. 1975;  12 339-351
  • 18 Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia.  Semin Hematol. 1999;  36 9-13
  • 19 Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines.  J Clin Oncol. 1999;  17 2954-2970
  • 20 Thiele J, Kvasnicka H M, Zankovich R, Diehl V. The value of bone marrow histology in differentiating between early stage polycythemia vera and secondary (reactive) polycythemias.  Haematologica. 2001;  86 368-374
  • 21 Thiele J, Kvasnicka H M, Orazi A. Bone marrow histopathology in myeloproliferative disorders-current diagnostic approach.  Semin Hematol. 2005;  42 184-195
  • 22 Georgii A, Buhr T, Buesche G, Kreft A, Choritz H. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies.  Leuk Lymphoma. 1996;  22(suppl 1) 15-29
  • 23 Harrison C N. Essential thrombocythaemia: challenges and evidence-based management.  Br J Haematol. 2005;  130 153-165
  • 24 Thiele J, Kvasnicka H M, Zankovich R, Diehl V. Early-stage idiopathic (primary) myelofibrosis-current issues of diagnostic features.  Leuk Lymphoma. 2002;  43 1035-1041
  • 25 Buhr T, Georgii A, Choritz H. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification.  Pathol Res Pract. 1993;  189 121-132
  • 26 Thiele J, Kvasnicka H M, Zankovich R, Diehl V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.  Haematologica. 2000;  85 1126-1134
  • 27 Thiele J, Kvasnicka H M, Schmitt-Graeff A, Diehl V. Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients.  Leuk Lymphoma. 2003;  44 949-953
  • 28 Thiele J, Kvasnicka H M, Schmitt-Graeff A, Zankovich R, Diehl V. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients.  Am J Hematol. 2002;  70 283-291
  • 29 Bellucci S, Janvier M, Tobelem G et al.. Essential thrombocythemias. Clinical evolutionary and biological data.  Cancer. 1986;  58 2440-2447
  • 30 Hehlmann R, Jahn M, Baumann B, Köpcke W. Essential thrombocythemia. Clinical characteristics and course of 61 cases.  Cancer. 1988;  61 2487-2496
  • 31 Fenaux P, Simon M, Caulier M T, Lai J L, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases.  Cancer. 1990;  66 549-556
  • 32 van Genderen P JJ, Mulder P GH, Waleboer M, van de Moesdijk D, Michiels J J. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin.  Br J Haematol. 1997;  97 179-184
  • 33 Michiels J J. Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia.  Clin Appl Thromb Hemost. 1999;  5 30-36
  • 34 Bazzan M, Tamponi G, Schinco P et al.. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia.  Ann Hematol. 1999;  78 539-543
  • 35 Passamonti F, Rumi E, Pungolino E et al.. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.  Am J Med. 2004;  117 755-761
  • 36 Michiels J J, Kutti J, Stark P et al.. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.  Neth J Med. 1999;  54 46-62
  • 37 Thiele J, Kvasnicka H M, Schmitt-Graeff A, Diehl V. Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis.  Histopathology. 2003;  43 470-479
  • 38 Thiele J, Kvasnicka H M, Fuchs N, Brunnbauer K, Volkwein N, Schmitt-Graeff A. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. An immunohistochemical and morphometric study of sequential trephine biopsies.  Haematologica. 2003;  88 1130-1138
  • 39 Mitus A J, Schafer A I. Thrombocytosis and thrombocythemia.  Hematol Oncol Clin North Am. 1990;  4 157-178
  • 40 Dawson A A, Ogston D. The influence of the platelet count on the incidence of thrombotic and haemorrhagic complications in polycythaemia vera.  Postgrad Med J. 1970;  46 76-78
  • 41 Barbui T, Cortelazzo S, Viero P, Bassan R, Dini E, Semeraro N. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.  Eur J Cancer Clin Oncol. 1983;  19 1593-1599
  • 42 Griesshammer M, Bangerter M, van Vliet H HDM, Michiels J J. Aspirin in essential thrombocythemia: status quo and quo vadis.  Semin Thromb Hemost. 1997;  23 371-377
  • 43 Michiels J J. Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts.  Pathol Biol (Paris). 2003;  51 167-175
  • 44 Michiels J J, Berneman Z N, Schroyens W, Van Vliet H HDM. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera.  Platelets. 2004;  15 67-84
  • 45 Schwarz J, Hrachovinova I, Vorlova Z, Salaj P. Thromboembolism in thrombocythemia patients with an additional thrombophilic state. (abst 974).  Hematol J. 2004;  5(suppl 2) S321
  • 46 Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts.  Am J Hematol. 1997;  56 168-172
  • 47 Storen E C, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia.  Blood. 2001;  97 863-866
  • 48 Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.  J Clin Oncol. 1990;  8 556-562
  • 49 Cortelazzo S, Finazzi G, Ruggeri M et al.. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.  N Engl J Med. 1995;  332 1132-1136
  • 50 Landolfi R, Marchioli R, Kutti J et al.. Efficacy and safety of low-dose aspirin in polycythemia vera.  N Engl J Med. 2004;  350 114-124
  • 51 Wehmeier A, Sudhoff T, Meierkord F. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.  Semin Thromb Hemost. 1997;  23 391-402
  • 52 Rao A K. Molecular and biochemical basis for the platelet dysfunction in myeloproliferative disorders.  Semin Hematol. 2004;  41(suppl 3) 6-9
  • 53 Tatewaki W, Shibata A. Acquired von Willebrand disease in patients with chronic myeloproliferative disorders.  Leuk Lymphoma. 1989;  1 51-57
  • 54 van Genderen P JJ, Michiels J J, van der Poel-van de Luytgaarde S CPAM, van Vliet H HDM. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count.  Ann Hematol. 1994;  69 81-84
  • 55 van Genderen P JJ, Budde U, Michiels J J, van Strik R, van Vliet H HDM. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count.  Br J Haematol. 1996;  93 962-965
  • 56 Michiels J J. Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia.  Clin Appl Thromb Hemost. 1999;  5 247-251
  • 57 Besses C, Cervantes F, Pereira A et al.. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients.  Leukemia. 1999;  13 150-154
  • 58 Randi M L, Fabris F, Rossi C, Tison T, Barbone E, Girolami A. Sex and age as prognostic factors in essential thrombocythemia.  Haematologica. 1992;  77 402-404
  • 59 Conlan M G, Haire W D. Low protein S in essential thrombocythemia with thrombosis.  Am J Hematol. 1989;  32 88-93
  • 60 Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.  Am J Hematol. 1996;  52 14-20
  • 61 Amitrano L, Guardascione M A, Ames P R et al.. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease.  Am J Hematol. 2003;  72 75-81
  • 62 Ruggeri M, Gisslinger H, Tosetto A et al.. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.  Am J Hematol. 2002;  71 1-6
  • 63 Gisslinger H, Mannhalter C, Pabinger I et al.. High risk of deep vein thrombosis in carriers of a prothrombin-gene mutation in patients with polycythemia vera and essential thrombocythemia. (abst 3144).  Blood. 2002;  100 796
  • 64 Kessler C M. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders.  Semin Hematol. 2004;  41(suppl 3) 10-14
  • 65 Barbui T, Barosi G, Grossi A et al.. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.  Haematologica. 2004;  89 215-232
  • 66 Harrison C N, Donohoe S, Carr P, Dave M, Mackie I, Machin S J. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis.  Thromb Haemost. 2002;  87 802-807
  • 67 Musolino C, Alonci A, Bellomo G et al.. Myeloproliferative disease: markers of endothelial and platelet status in patients with essential thrombocythemia and polycythemia vera.  Hematology. 2000;  4 397-402
  • 68 Musolino C, Calabro L, Bellomo G et al.. Soluble angiogenic factors: implications for chronic myeloproliferative disorders.  Am J Hematol. 2002;  69 159-163
  • 69 Teofili L, Pierconti F, Di Febo A et al.. The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia.  Blood. 2002;  100 714-717
  • 70 Harrison C N, Gale R E, Machin S J, Linch D C. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications.  Blood. 1999;  93 417-424
  • 71 Wolanskyj A P, Lasho T L, Schwager S M et al.. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.  Br J Haematol. 2005;  131 208-213
  • 72 Gisslinger H, Rodeghiero F, Ruggeri M et al.. Homocysteine levels in polycythaemia vera and essential thrombocythaemia.  Br J Haematol. 1999;  105 551-555
  • 73 Griesshammer M, Grünewald M, Michiels J J. Acquired thrombophilia in pregnancy: essential thrombocythemia.  Semin Thromb Hemost. 2003;  29 205-212
  • 74 Ruggeri Z, Cannata M L, Stella N C, Corrado F. Pregnancy in essential thrombocythemia during aspirin treatment.  Arch Gynecol Obstet. 2003;  268 209-210
  • 75 Schafer A I, Levine M N, Konkle B A, Kearon C. Thrombotic disorders: diagnosis and treatment.  Hematology (Am Soc Hematol Educ Program). 2005;  520-539
  • 76 Falanga A. Thrombosis and malignancy: an underestimated problem.  Haematologica. 2003;  88 607-610
  • 77 Freytes C O. Thromboembolic complications related to indwelling central venous catheters in children: a neglected aspect of the study of vascular access devices.  Opin Top Supp Care Oncol. 2002;  42 7-8
  • 78 Tripodi A. Levels of coagulation factors and venous thromboembolism.  Haematologica. 2003;  88 705-711
  • 79 Nowak-Göttl U, Kosch A, Schlegel N, Salem M, Manco-Johnson M. Thromboembolism in children.  Curr Opin Hematol. 2002;  9 448-453
  • 80 Harrison C N, Campbell P J, Buck G et al.. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.  N Engl J Med. 2005;  353 33-45
  • 81 Chistolini A, Mazzucconi M G, Ferrari A et al.. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients.  Haematologica. 1990;  75 537-540
  • 82 Balan K K, Critchley M. Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32 - a 15 year review.  Br J Radiol. 1997;  70 1169-1173
  • 83 Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients.  Acta Haematol. 1991;  85 124-127
  • 84 Okamura T, Kinukawa N, Niho Y, Mizoguchi H. Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients.  Int J Hematol. 2001;  73 194-198
  • 85 Pettit J E. The non-leukaemic myeloproliferative disorders. In: Hoffbrand AV, Lewis SM Postgraduate Haematology. 2nd ed. London; Heinemann 1981: 577-604
  • 86 Najean Y, Rain J-D. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years.  Blood. 1997;  90 3370-3377
  • 87 Fruchtman S M. Treatment paradigms in the management of myeloproliferative disorders.  Semin Hematol. 2004;  41(suppl 3) 18-22
  • 88 Briere J, Guilmin F. Management of patients with essential thrombocythemia: current concepts and perspectives.  Pathol Biol (Paris). 2001;  49 178-183
  • 89 Barbui T. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?.  Semin Hematol. 2004;  41(suppl 3) 15-17
  • 90 Yarbro J W. Mechanism of action of hydroxyurea.  Semin Oncol. 1992;  19(suppl 9) 1-10
  • 91 Hong Y, Erusalimsky J D. Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review.  Platelets. 2002;  13 381-386
  • 92 Raposa T, Várkonyi J. The relationship between sister chromatid exchange induction and leukemogenicity of different cytostatics.  Cancer Detect Prev. 1987;  10 141-151
  • 93 Mehnert K, Vogel W, Benz R, Speit G. Different effects of mutagens on sister chromatid exchange induction in three Chinese hamster cell lines.  Environ Mutagen. 1984;  6 573-583
  • 94 Schroeder A L. Chromosome instability in mutagen sensitive mutants of Neurospora.  Curr Genet. 1986;  10 381-387
  • 95 Seino Y, Nagao M, Yahagi T, Hoshi A, Kawachi T, Sugimura T. Mutagenicity of several classes of antitumor agents to Salmonella typhimurium TA98, TA100, and TA92.  Cancer Res. 1978;  38 2148-2156
  • 96 Marsteinstredet U, Brunborg G, Bjoras M et al.. DNA damage induced by 3-chloro-4-(dichloromethyl)-5-hydroxy-2[5H]-furanone (MX) in HL-60 cells and purified DNA in vitro.  Mutat Res. 1997;  390 171-178
  • 97 Andersson M, Agurell E, Vaghef H, Bolcsfoldi G, Hellman B. Extended-term cultures of human T-lymphocytes and the comet assay: a useful combination when testing for genotoxicity in vitro?.  Mutat Res. 2003;  540 43-55
  • 98 Ficsor G, Ginsberg L C. The effect of hydroxyurea and mitomycin C on sperm motility in mice.  Mutat Res. 1980;  70 383-387
  • 99 Nand S, Messmore H, Fisher S G, Bird M L, Schulz W, Fisher R I. Leukemic transformation in polycythemia vera: analysis of risk factors.  Am J Hematol. 1990;  34 32-36
  • 100 Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications.  Eur J Haematol. 1994;  52 134-139
  • 101 Randi M L, Fabris F, Girolami A. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.  Leuk Lymphoma. 2000;  37 379-385
  • 102 Nielsen I, Hasselbalch H C. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.  Am J Hematol. 2003;  74 26-31
  • 103 Sterkers Y, Preudhomme C, Lai J L et al.. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.  Blood. 1998;  91 616-622
  • 104 Tóthová E, Fričová M, Štecová N et al.. Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17.  Neoplasma. 2001;  48 389-392
  • 105 Finazzi G, Caruso V, Marchioli R et al.. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.  Blood. 2005;  105 2664-2670
  • 106 Marchioli R, Finazzi G, Landolfi R et al.. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.  J Clin Oncol. 2005;  23 2224-2232
  • 107 Finazzi G, Barbui T. Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.  Pathol Biol (Paris). 2001;  49 167-169
  • 108 Barbui T. Indications for lowering platelet numbers in essential thrombocythemia.  Semin Hematol. 2003;  40 22-25
  • 109 Falanga A, Marchetti M, Evangelista V et al.. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.  Blood. 2000;  96 4261-4266
  • 110 Falanga A, Marchetti M, Barbui T, Smith C W. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils.  Semin Hematol. 2005;  42 239-247
  • 111 Lofvenberg E, Nordenson I, Wahlin A. Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease.  Cancer Genet Cytogenet. 1990;  49 57-67
  • 112 Lengfelder E, Griesshammer M, Hehlmann R. Interferon-alpha in the treatment of essential thrombocythemia.  Leuk Lymphoma. 1996;  22(suppl 1) 135-142
  • 113 Alvarado Y, Cortes J, Verstovsek S et al.. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia.  Cancer Chemother Pharmacol. 2003;  51 81-86
  • 114 Anagrelide Study Group . Anagrelide, a therapy for thrombocythemic states: experience in 577 patients.  Am J Med. 1992;  92 69-76
  • 115 Petrides P E. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.  Expert Opin Pharmacother. 2004;  5 1781-1798
  • 116 Petitt R M, Silverstein M N, Petrone M E. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders.  Semin Hematol. 1997;  34 51-54
  • 117 Gisslinger H. Management of essential thrombocythemia.  Hematology (Am Soc Hematol Educ Program). 2005;  1 105-110
  • 118 Tefferi A, Barbui T. bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment.  Mayo Clin Proc. 2005;  80 1220-1232
  • 119 Finazzi G, Harrison C. Essential thrombocythemia.  Semin Hematol. 2005;  42 230-238
  • 120 Barbui T, Finazzi G. When and how to treat essential thrombocythemia.  N Engl J Med. 2005;  353 85-86
  • 121 Thiele J, Kvasnicka H M, Schmitt-Gräff A, Hülsemann R, Diehl V. Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis.  Histol Histopathol. 2004;  19 239-250
  • 122 Steurer M, Gastl G, Jedrzejczak W W et al.. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.  Cancer. 2004;  101 2239-2246
  • 123 Zweegman S, de Groot M R, Sonneveld P. The HOVON 58 study: pegylated interferon-2A or anagrelide in high risk essential thrombocythemia: a randomized phase II trial. Observational study of low and intermediate risk patients. Rotterdam, The Netherlands; European Working Group on Myeloproliferative Disorders 2004: 79-80
  • 124 Gilbert H S. The role of anagrelide, hydroxyurea, and interferon-α in treating the thrombocythemia of myeloproliferative disease: a new approach for the millennium. Presented at: the XVth Meeting of the International Society of Haematology, African & European Division, Durban, South Africa September 18-23,1999: 141-143
  • 125 Marchioli R, Finazzi G, Marfisi R M, Tognoni G, Barbui T. Clinical trials in myeloproliferative disorders: looking forward.  Semin Hematol. 2005;  42 259-265

Jiři SchwarzM.D. 

Institute of Hematology and Blood Transfusion

U Nemocnice 1, 128 20, Prague 2, Czech Republic

Email: jiri.schwarz@uhkt.cz